Description

Introducing Risperidone Tablets by PharmAlliance International Labs Private Limited

Welcome to PharmAlliance International Labs, where our commitment to global health drives us to deliver pharmaceutical excellence. Our Risperidone Tablets stand as a testament to our dedication to providing innovative solutions for psychiatric disorders, ensuring the well-being of individuals worldwide.

Drug Classification:

Risperidone, a cornerstone in psychiatric pharmacotherapy, belongs to the class of atypical antipsychotics. Renowned for its efficacy, it modulates dopamine and serotonin receptors in the brain, offering relief from symptoms associated with psychotic disorders.

Formulations:

• Risperidone Tablets:
• Strength: Available in 1mg, 2mg, 3mg, and 4mg tablets.
• Product Form: Oral tablets for convenient administration.
• Packing Specs: Each pack contains 20 tablets.

Indications:

Risperidone Tablets are indicated for the treatment of various psychiatric disorders, encompassing:

• Schizophrenia: Managing a spectrum of symptoms including hallucinations, delusions, disorganized thinking, and emotional disturbances characteristic of schizophrenia.
• Bipolar Disorder: Addressing acute manic or mixed episodes, as well as serving as maintenance therapy to forestall the recurrence of manic episodes in individuals with bipolar I disorder.
• Irritability Associated with Autism Spectrum Disorder: Alleviating irritability and aggression in pediatric patients aged 5 to 16 years grappling with autism spectrum disorder.

Usage:

Risperidone Tablets should be orally administered once daily, with or without food, in accordance with healthcare provider guidance. Adherence to prescribed dosage and treatment regimens is paramount to achieving optimal therapeutic outcomes. Dosage adjustments should be undertaken cautiously under healthcare professional supervision, tailored to individual response and tolerability.

Dosage:

The recommended initial dosage of Risperidone for schizophrenia in adults ranges from 1mg to 2mg once daily, with gradual titration up to a maximum of 8mg per day based on therapeutic response.

For bipolar disorder, the initial dosage typically spans from 2mg to 3mg once daily, with maintenance dosages ranging from 1mg to 6mg per day.

Pediatric patients with autism spectrum disorder may commence treatment at a dosage of 0.25mg to 0.5mg once daily, with incremental titration to a maximum of 3.5mg per day guided by response and tolerability.

Pharmacokinetics:

Risperidone exhibits rapid absorption post-oral administration, with peak plasma concentrations attained within 1 to 2 hours. Hepatic metabolism, predominantly mediated by the CYP2D6 enzyme system, yields an active metabolite, 9-hydroxyrisperidone. The elimination half-life of both risperidone and its metabolite ranges from 20 to 30 hours, facilitating once-daily dosing regimens.

Pharmacodynamics:

Through antagonism of dopamine D2 and serotonin 5-HT2A receptors in the central nervous system, risperidone modulates dopaminergic and serotonergic neurotransmission. This mechanism effectively mitigates positive and negative symptoms associated with schizophrenia and bipolar disorder, enhancing psychosocial functioning and quality of life.

Side Effects:

Common side effects of Risperidone Tablets may encompass drowsiness, dizziness, weight gain, constipation, and dry mouth. Extrapyramidal symptoms like tremor, akathisia, and dystonia may manifest, particularly at higher dosages. Metabolic adverse effects, including hyperglycemia, dyslipidemia, and weight gain, necessitate vigilant monitoring of metabolic parameters.

Trust in the efficacy and safety of Risperidone Tablets from PharmAlliance International Labs Private Limited. We are steadfast in our mission to support individuals grappling with psychiatric disorders, empowering them with the treatment needed to lead fulfilling lives. For further insights, please visit our website or consult your healthcare provider.